← Back to home

P16-POSITIVE SQUAMOUS CELL CARCINOMA OF THE PHARYNX, LARYNX OR ORAL CAVITY

Clinical trials for P16-POSITIVE SQUAMOUS CELL CARCINOMA OF THE PHARYNX, LARYNX OR ORAL CAVITY explained in plain language.

Never miss a new study

Get alerted when new P16-POSITIVE SQUAMOUS CELL CARCINOMA OF THE PHARYNX, LARYNX OR ORAL CAVITY trials appear

Sign up with your email to follow new studies for P16-POSITIVE SQUAMOUS CELL CARCINOMA OF THE PHARYNX, LARYNX OR ORAL CAVITY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Immunotherapy may replace chemo in head and neck cancer trial

Disease control Ongoing

This study tests whether the immunotherapy drug pembrolizumab (Keytruda) combined with radiation works better than the standard chemotherapy drug cisplatin with radiation for patients with a certain type of head and neck cancer (p16-positive). About 126 adults with advanced or in…

Matched conditions: P16-POSITIVE SQUAMOUS CELL CARCINOMA OF THE PHARYNX, LARYNX OR ORAL CAVITY

Phase: PHASE2 • Sponsor: Loren Mell, MD • Aim: Disease control

Last updated Jun 16, 2026 12:55 UTC

P16-POSITIVE SQUAMOUS CELL CARCINOMA OF THE PHARYNX, LARYNX OR ORAL CAVITY

Get alerted when new P16-POSITIVE SQUAMOUS CELL CARCINOMA OF THE PHARYNX, LARYNX OR ORAL CAVITY trials appear

Immunotherapy may replace chemo in head and neck cancer trial